← back to search

Marie‐Christine Kaminsky

Institut de Cancérologie de Lorraine · FR
Area of research
Oncology · Reproductive Medicine
Research interest
Research interests include Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, BRCA gene mutations in cancer, and Head and Neck Cancer Studies.
h-index
29
citations
4,880
works
130
NIH funding
primary concept
Medicine
email

Recent publications

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
Journal of Clinical Oncology 2023cited by 100position: middledoi
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial
Gynecologic Oncology 2023cited by 27position: middledoi
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology 2021cited by 409position: middledoi
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial
European Journal of Cancer 2021cited by 54position: middledoi
Mucoepidermoid carcinoma of salivary glands: A French Network of Rare Head and Neck Tumors (REFCOR) prospective study of 292 cases
European Journal of Surgical Oncology 2020cited by 33position: middledoi
Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy
European Journal of Cancer 2019cited by 43position: middledoi
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology 2017cited by 1,857position: middledoi
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group
British Journal of Cancer 2017cited by 66position: middledoi
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
European Journal of Cancer 2017cited by 45position: middledoi
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
Annals of Oncology 2013cited by 103position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Alain Lortholary · Hôpital Tenon2 papers (2017–2019)Anne Lesoin · KU Leuven2 papers (2017–2019) · 1 papers (2017–2017)Sylvie Zanetta · Klinikum Stuttgart1 papers (2021–2021)Christophe Le Tourneau · Inserm1 papers (2021–2021)Frédèric Selle · Hospices Civils de Lyon1 papers (2017–2017) · 1 papers (2021–2021) · 1 papers (2021–2021)Chee Khoon Lee · Liverpool Hospital1 papers (2019–2019)Anthony Kong · Hong Kong Polytechnic University1 papers (2021–2021)Éric Pujade-Lauraine · Hospital Universitario Ramón y Cajal1 papers (2019–2019)Philip R. Debruyne · AZ Groeninge1 papers (2021–2021)Isabelle Ray‐Coquard · Université Claude Bernard Lyon 11 papers (2017–2017)Benoît You · Communauté urbaine de Lyon1 papers (2017–2017) · 1 papers (2017–2017)Rachel Galot · UCLouvain1 papers (2021–2021)Stéphanie Henry · UCLouvain1 papers (2021–2021) · 1 papers (2021–2021)Isabelle Treilleux · Université Claude Bernard Lyon 11 papers (2017–2017)Elsa Kalbacher · Universitair Ziekenhuis Leuven1 papers (2017–2017)